EJEric J. Jaehnig

Eric J. Jaehnig

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Eric J. Jaehnig has a total of 262 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comprehensive Proteogenomic Characterization of the DNA Damage Response (DDR) across Human Tumors Spanning Ten Cancer Types

    by Eric J. Jaehnig, Anh M. Tran-Huynh, Meenakshi Anurag, See Pdf

    Defects in DNA damage response (DDR) pathways drive genomic instability and influence therapeutic vulnerabilities in cancer. We integrated CPTAC proteomic and phosphoproteomic data with genomic data to interrogate DDR pathways across 10 cancer types, extending the prior TCGA pan-cancer DDR genomic study [1]. Expression-based DDR pathway activity scores inferred from transcriptomic and proteomic data were concordant and positively correlated with chromosomal instability and proliferative signaling. Low DDR inferred activity, in contrast, correlated with epithelial-mesenchymal transition, innate immune features, and metabolic hallmark pathways. Germline DDR variants influenced tumor gene and protein expression, and pathogenic mutation carriers exhibited elevated homologous recombination deficiency signatures. L1 retrotransposon expression was correlated with heightened chromosomal instability and DDR signaling activity, while tumors harboring TP53 mutations demonstrated distinct protein expression patterns and CDK family kinase enrichment. These results collectively reveal new links among DDR pathways, genomic alterations and proteomic/phosphoproteomic signatures across diverse cancer types.

  • NF1-depleted ER + breast cancers are differentially sensitive to CDK4/6 inhibitors

    by Ze-Yi Zheng, Anran Chen, Eric J. Jaehnig, Meenakshi Anurag, Jonathan T. Lei, Long Feng, Chenwei Wang, Diana Fandino, Purba Singh, Hilda Kennedy, et al.

    Neurofibromin/NF1 is a RAS (rat sarcoma virus) GTPase-activating protein and estrogen receptor (ER) transcriptional corepressor. NF1 low status, identified by copy number loss or low mRNA/protein expression, is associated with endocrine therapy resistance in ~20% of ER + /HER2 − (human epidermal growth factor receptor 2) early-stage breast cancers. The identification of targeted treatments for NF1 low ER + /HER2 − breast cancer is therefore a priority. In this study, proteogenomic analysis of ER + /HER2 − breast cancer demonstrated that NF1 low tumors exhibited elevated cyclin-dependent kinase 4/6 (CDK4/6) activity. In cell lines, NF1 deletion had a dual effect on CDK4 activity: first, by promoting ER recruitment to CCND1 (cyclin D1), thereby increasing CDK4–cyclin D1 complex formation, and second, by activating C-RAF (rapidly accelerated fibrosarcoma), which drove phosphorylation of the CDK4 activation loop. Preclinical modeling demonstrated that NF1 low ER + cancer cells were more sensitive to fulvestrant combined with a CDK4/6 inhibitor versus fulvestrant alone, with the induction of cell death in vitro and durable tumor regressions in ER + NF1 low patient-derived xenograft models in vivo. Furthermore, NF1 low ER + /HER2 − tumors were more sensitive to neoadjuvant aromatase inhibitor (AI) plus palbociclib than to neoadjuvant AI alone, as indicated by suppression of mRNA-based proliferation scores. These data are consistent with a model whereby ER and RAS coactivation upon NF1 loss can drive CDK4/6 activity and endocrine therapy resistance but renders NF1 low ER + tumors susceptible to CDK4/6 inhibition. Development of clinical-grade NF1 diagnostics should be prioritized to determine whether NF1 low ER + breast cancers should receive adjusted adjuvant treatment recommendations that reflect increased responsiveness to CDK4/6 inhibition.


  • Top Cited Papers
    Open Access

    Comprehensive evaluation of phosphoproteomic-based kinase activity inference

    by Sophia Müller-Dott, Eric J. Jaehnig, Khoi Pham Munchic, Wen Jiang, Tomer M. Yaron-Barir, Sara R. Savage, Martin Garrido-Rodriguez, Jared L. Johnson, Alessandro Lussana, Evangelia Petsalaki, et al.

    Kinases regulate cellular processes and are essential for understanding cellular function and disease. To investigate the regulatory state of a kinase, numerous methods have been developed to infer kinase activities from phosphoproteomics data using kinase-substrate libraries. However, few phosphorylation sites can be attributed to an upstream kinase in these libraries, limiting the scope of kinase activity inference. Moreover, inferred activities vary across methods, necessitating evaluation for accurate interpretation. Here, we present benchmarKIN, an R package enabling comprehensive evaluation of kinase activity inference methods. Alongside classical perturbation experiments, benchmarKIN introduces a tumor-based benchmarking approach utilizing multi-omics data to identify highly active or inactive kinases. We used benchmarKIN to evaluate kinase-substrate libraries, inference algorithms and the potential of adding predicted kinase-substrate interactions to overcome the coverage limitations. Our evaluation shows most computational methods perform similarly, but the choice of library impacts the inferred activities with a combination of manually curated libraries demonstrating superior performance in recapitulating kinase activities. Additionally, in the tumor-based evaluation, adding predicted targets from NetworKIN further boosts the performance. We then demonstrate how kinase activity inference aids characterize kinase inhibitor responses in cell lines. Overall, benchmarKIN helps researchers to select reliable methods for identifying deregulated kinases.


  • Open Access

    Deciphering the dark cancer phosphoproteome using machine-learned co-regulation of phosphosites

    by Wen Jiang, Eric J. Jaehnig, Yuxing Liao, Zhiao Shi, Tomer M. Yaron-Barir, Jared L. Johnson, Lewis C. Cantley, Bing Zhang

    Mass spectrometry-based phosphoproteomics offers a comprehensive view of protein phosphorylation, yet our limited knowledge about the regulation and function of most phosphosites hampers the extraction of meaningful biological insights. To address this challenge, we integrate machine learning with phosphoproteomic data from 1195 tumor specimens spanning 11 cancer types to construct CoPheeMap, a network that maps the co-regulation of 26,280 phosphosites. By incorporating network features from CoPheeMap into a second machine learning model, namely CoPheeKSA, we achieve superior performance in predicting kinase-substrate associations. CoPheeKSA uncovers 24,015 associations between 9399 phosphosites and 104 serine/threonine kinases, shedding light on many unannotated phosphosites and understudied kinases. We validate the accuracy of these predictions using experimentally determined kinase-substrate specificities. Through the application of CoPheeMap and CoPheeKSA to phosphosites with high computationally predicted functional significance and those associated with cancer, we demonstrate their effectiveness in systematically elucidating phosphosites of interest. These analyses unveil dysregulated signaling processes in human cancer and identify understudied kinases as potential therapeutic targets.


  • Open Access

    Comprehensive evaluation of phosphoproteomic-based kinase activity inference

    by Sophia Müller-Dott, Eric J. Jaehnig, Khoi Pham Munchic, Wen Jiang, Tomer M. Yaron-Barir, Sara R. Savage, Martin Garrido-Rodriguez, Jared L. Johnson, Alessandro Lussana, Evangelia Petsalaki, et al.

    Kinases play a central role in regulating cellular processes, making their study essential for understanding cellular function and disease mechanisms. To investigate the regulatory state of a kinase, numerous methods have been, and continue to be, developed to infer kinase activities from phosphoproteomics data. These methods usually rely on a set of kinase targets collected from various kinase-substrate libraries. However, only a small percentage of measured phosphorylation sites can usually be attributed to an upstream kinase in these libraries, limiting the scope of kinase activity inference. In addition, the inferred activities from different methods can vary making it crucial to evaluate them for accurate interpretation. Here, we present a comprehensive evaluation of kinase activity inference methods using multiple kinase-substrate libraries combined with different inference algorithms. Additionally, we try to overcome the coverage limitations for measured targets in kinase substrate libraries by adding predicted kinase-substrate interactions for activity inference. For the evaluation, in addition to classical cell-based perturbation experiments, we introduce a tumor-based benchmarking approach that utilizes multi-omics data to identify highly active or inactive kinases per tumor type. We show that while most computational algorithms perform comparably regardless of their complexity, the choice of kinase-substrate library can highly impact the inferred kinase activities. Hereby, manually curated libraries, particularly PhosphoSitePlus, demonstrate superior performance in recapitulating kinase activities from phosphoproteomics data. Additionally, in the tumor-based evaluation, adding predicted targets from NetworKIN further boosts the performance, while normalizing sites to host protein levels reduces kinase activity inference performance. We then showcase how kinase activity inference can help in characterizing the response to kinase inhibitors in different cell lines. Overall, the selection of reliable kinase activity inference methods is important in identifying deregulated kinases and novel drug targets. Finally, to facilitate the evaluation of novel methods in the future, we provide both benchmarking approaches in the R package benchmarKIN. Graphical


  • Open Access

    Deep Learning Prediction Boosts Phosphoproteomics-Based Discoveries Through Improved Phosphopeptide Identification

    by Xinpei Yi, Bo Wen, Shuyi Ji, Alexander B. Saltzman, Eric J. Jaehnig, Jonathan T. Lei, Qiang Gao, Bing Zhang


  • Open Access

    IDPpub: Illuminating the Dark Phosphoproteome Through PubMed Mining

    by Sara R. Savage, Yaoyun Zhang, Eric J. Jaehnig, Yuxing Liao, Zhiao Shi, Huy Anh Pham, Hua Xu, Bing Zhang


  • Open Access

    FIGURE 2 from Kinase Inhibitor Pulldown Assay Identifies a Chemotherapy Response Signature in Triple-negative Breast Cancer Based on Purine-binding Proteins

    by Junkai Wang, Alexander B. Saltzman, Eric J. Jaehnig, Jonathan T. Lei, Anna Malovannaya, Matthew V. Holt, Meggie N. Young, Mothaffar F. Rimawi, Foluso O. Ademuyiwa, Meenakshi Anurag, et al.

    Differential protein analysis between pCR and non-pCR samples. A, Volcano plot shows results from differential analysis between pCR and non-pCR samples with the KIPA. X-axis is the log10 fold change between median value of pCR and non-pCR samples for each protein. Y-axis is the −log10P-value from Wilcoxon rank-sum tests comparing protein levels in pCR samples to non-pCR samples. Red and blue points indicate the most significant (P < 0.01) proteins, and pink and light blue points indicate significant (0.01 < P < 0.05) proteins. B, Heat map shows the levels of seven PBP signature genes across 43 samples, arranged by RCB class (0, I, II, II) and the KIPA-based PBP signature score. The levels of seven genes were assessed at the level of KIPA (orange), protein (light blue), and mRNA (pink), and normalized across all samples by z-score. P values were determined by Wilcoxon rank-sum tests comparing gene levels for pCR samples to non-pCR samples. PBP signature, purine-binding protein signature.

  • Open Access

    Supplementary Figure 4 from Kinase Inhibitor Pulldown Assay Identifies a Chemotherapy Response Signature in Triple-negative Breast Cancer Based on Purine-binding Proteins

    by Junkai Wang, Alexander B. Saltzman, Eric J. Jaehnig, Jonathan T. Lei, Anna Malovannaya, Matthew V. Holt, Meggie N. Young, Mothaffar F. Rimawi, Foluso O. Ademuyiwa, Meenakshi Anurag, et al.

  • Open Access

    Supplementary Table S1-S5 from Kinase Inhibitor Pulldown Assay Identifies a Chemotherapy Response Signature in Triple-negative Breast Cancer Based on Purine-binding Proteins

    by Junkai Wang, Alexander B. Saltzman, Eric J. Jaehnig, Jonathan T. Lei, Anna Malovannaya, Matthew V. Holt, Meggie N. Young, Mothaffar F. Rimawi, Foluso O. Ademuyiwa, Meenakshi Anurag, et al.

    Supplementary Table S1-S5 from Kinase Inhibitor Pulldown Assay Identifies a Chemotherapy Response Signature in Triple-negative Breast Cancer Based on Purine-binding Proteins